STEP-TEENS
The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.
Definition
Trial of semaglutide 2.4 mg in adolescents 12-17 with obesity (Weghuber et al, NEJM 2022). Mean weight reduction 16.7% vs 0.6% placebo. Pediatric trials do not measure facial appearance as an outcome.
STEP-TEENS adolescent semaglutide →
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Major trials
Looking for more depth?
- STEP-TEENS adolescent semaglutide
- Browse the full GLP-1 glossary (51 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers